David Risinger
Stock Analyst at Leerink Partners
(4.47)
# 248
Out of 4,868 analysts
170
Total ratings
65.17%
Success rate
13.48%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $149.71 | +2.20% | 4 | May 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Market Perform | $550 → $503 | $439.81 | +14.37% | 4 | May 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $511.63 | +63.01% | 8 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $185.05 | +11.32% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.96 | +55.47% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $19.61 | +251.86% | 2 | Nov 11, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | $16 | $5.44 | +194.12% | 1 | Oct 24, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $44 | $11.71 | +275.75% | 2 | Sep 17, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $106 → $153 | $32.80 | +366.46% | 2 | Sep 3, 2024 | |
| TBPH Theravance Biopharma | Downgrades: Market Perform | $15 → $10 | $10.66 | -6.19% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $28 → $2 | $1.86 | +7.82% | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $22.84 | +105.82% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $291.86 | +8.96% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $12.54 | -12.28% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $410 → $458 | $764.47 | -40.09% | 16 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $42 | $53.05 | -20.83% | 3 | Mar 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $109.19 | -16.66% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $23.91 | +100.79% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $11.45 | -12.63% | 4 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $10 | $29.56 | -66.16% | 2 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $9.72 | +280.85% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $107.70 | +63.42% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $8.83 | +81.30% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $26.45 | +70.13% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.10 | +474.24% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $13.45 | +204.95% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $156.83 | +10.95% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $34.68 | +47.06% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $17.08 | -53.15% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $79.62 | +11.78% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $7.81 | -61.56% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $29.07 | -44.96% | 9 | Apr 2, 2020 |
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $149.71
Upside: +2.20%
Vertex Pharmaceuticals
May 6, 2025
Downgrades: Market Perform
Price Target: $550 → $503
Current: $439.81
Upside: +14.37%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $511.63
Upside: +63.01%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $185.05
Upside: +11.32%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.96
Upside: +55.47%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $19.61
Upside: +251.86%
Tenax Therapeutics
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $5.44
Upside: +194.12%
Oruka Therapeutics
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $11.71
Upside: +275.75%
Vaxcyte
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $32.80
Upside: +366.46%
Theravance Biopharma
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $10.66
Upside: -6.19%
Jul 9, 2024
Downgrades: Market Perform
Price Target: $28 → $2
Current: $1.86
Upside: +7.82%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $22.84
Upside: +105.82%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $291.86
Upside: +8.96%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $12.54
Upside: -12.28%
May 1, 2023
Maintains: Outperform
Price Target: $410 → $458
Current: $764.47
Upside: -40.09%
Mar 16, 2023
Downgrades: Market Perform
Price Target: $42
Current: $53.05
Upside: -20.83%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $109.19
Upside: -16.66%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $23.91
Upside: +100.79%
Dec 19, 2022
Maintains: Outperform
Price Target: $8 → $10
Current: $11.45
Upside: -12.63%
Jun 24, 2022
Maintains: Market Perform
Price Target: $7 → $10
Current: $29.56
Upside: -66.16%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $9.72
Upside: +280.85%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $107.70
Upside: +63.42%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $8.83
Upside: +81.30%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $26.45
Upside: +70.13%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.10
Upside: +474.24%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $13.45
Upside: +204.95%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $156.83
Upside: +10.95%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $34.68
Upside: +47.06%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $17.08
Upside: -53.15%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $79.62
Upside: +11.78%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $7.81
Upside: -61.56%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $29.07
Upside: -44.96%